Industry / Mexico
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Grupo Casa Saba Reports Modest Growth
February 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Grupo Casa Saba (GCS)'s uninspiring Q407 results have underlined BMI's warning that the domestic distribution giant must look to international expansion or for a foreign tie up if it is to increase turnover. Fourth quarter sales grew by 3.85% compared with Q406 to reach US$7.1bn, while profits reached US$383.9mn. Sales in GCS's private pharmaceutical division, which accounts for over 80% of revenue, grew by just 3.66%. When compared with overall pharmaceutical market growth, which BMI estimates to have been 9% in 2007, these results look doubly